Valuation: Becton, Dickinson and Company

Market Cap 50.07B 44.04B 41.64B 37.77B 70.94B 4,807B 71.35B 499B 193B 2,453B 188B 184B 7,882B P/E 2026 *
35.4x
P/E 2027 * 19.7x
Enterprise Value 65.96B 58.01B 54.86B 49.75B 93.44B 6,331B 93.98B 657B 254B 3,231B 248B 242B 10,382B EV / Sales 2026 *
3.42x
EV / Sales 2027 * 3.24x
Free-Float
73.18%
Yield 2026 *
2.13%
Yield 2027 * 2.17%
1 day+1.06%
1 week+1.95%
Current month-1.60%
1 month-1.60%
3 months+16.68%
6 months+18.36%
Current year-3.44%
1 week 157.2
Extreme 157.2
161.65
1 month 151.45
Extreme 151.45
163.65
Current year 121
Extreme 121
179
1 year 121
Extreme 121
179
3 years 121
Extreme 121
253.5
5 years 121
Extreme 121
265
10 years 121
Extreme 121
265
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.11%+1.95% - - 50.07B
-0.31%-1.94%-24.39%+2.91% 175B
+0.97%-2.45%-5.01%+13.74% 114B
-1.01%-4.01%-1.04%+66.14% 57.98B
+0.01%+1.73%-0.42%-30.03% 50.07B
-1.00%+0.37%+14.24%+51.55% 50.13B
+0.07%-2.79%+29.18%-9.20% 32.71B
+1.07%+9.73% - - 30.77B
+1.41%+3.83%+43.64%-0.90% 26.44B
+1.57%+6.59%+28.62%-2.65% 23.96B
Average +0.38%+1.59%+10.60%+11.44% 62.36B
Weighted average by Cap. +0.18%-0.18%-2.65%+12.46%

Financials

2026 *2027 *
Net sales 19.26B 16.94B 16.02B 14.53B 27.29B 1,849B 27.44B 192B 74.07B 943B 72.31B 70.75B 3,032B 19.73B 17.36B 16.41B 14.89B 27.96B 1,894B 28.12B 196B 75.89B 967B 74.09B 72.48B 3,106B
Net income 1.44B 1.26B 1.19B 1.08B 2.04B 138B 2.05B 14.31B 5.52B 70.37B 5.39B 5.28B 226B 2.34B 2.06B 1.95B 1.76B 3.31B 225B 3.33B 23.3B 9B 115B 8.78B 8.59B 368B
Net Debt 15.88B 13.97B 13.21B 11.98B 22.5B 1,525B 22.63B 158B 61.09B 778B 59.64B 58.35B 2,500B 13.95B 12.27B 11.6B 10.52B 19.76B 1,339B 19.88B 139B 53.66B 683B 52.38B 51.25B 2,196B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Date Price Change Volume
29/09/26 €159.85 -0.12% 0
28/09/26 €160.05 +1.81% 0
25/09/26 €157.20 -2.75% 0
24/09/26 €161.65 +1.32% 30
23/09/26 €159.55 +1.75% 0
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
183.83USD
Average target price
195.67USD
Spread / Average Target
+6.44%

Quarterly revenue - Rate of surprise